Aardvark Therapeutics (AARD) Common Equity (2024 - 2026)

Aardvark Therapeutics (AARD) has 3 years of Common Equity data on file, last reported at $87.0 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 42.27% year-over-year to $87.0 million; the trailing twelve-month figure through Mar 2026 stood at $87.0 million (down 42.27% YoY), and the FY2025 full-year result was $106.6 million, up 295.14% from the prior year.
• Common Equity retreated to $87.0 million in Q1 2026, from $106.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $150.7 million in Q1 2025 to a low of -$54.6 million in Q4 2024.
• A 3-year average of $47.1 million and a median of $87.0 million in 2026 frame the typical range for Common Equity.
• Across the five-year window, Common Equity surged 508.25% in 2025 and sank 42.27% in 2026, its largest moves.
• Tracing AARD's Common Equity over 3 years: stood at -$54.6 million in 2024, then jumped by 295.14% to $106.6 million in 2025, then slipped by 18.42% to $87.0 million in 2026.
• Business Quant data shows AARD's Common Equity at $87.0 million in Q1 2026, $106.6 million in Q4 2025, and $122.4 million in Q3 2025.